RecruitingNCT02471378

Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates

In-Vitro Testing of Pregnancy Malaria Vaccine Candidates


Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

7,476 participants

Start Date

Jul 28, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

Background: \- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away. Children younger than 5 and pregnant women are most at risk to get malaria. Researchers want to create a vaccine that will prevent malaria infection during pregnancy. Objectives: \- To create a vaccine that will prevent malaria infection during pregnancy. To assess possible vaccines using in-vitro tests with parasites taken from pregnant women. Eligibility: \- Pregnant women ages 15-25 Design: * The study site is an area in Mali, West Africa. * Participants: * Will have blood drawn. * Will give consent for the blood sample to be used for future research. * May have a physical exam. * Participants who have malaria or anemia will get treatment.


Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 25 Years

Inclusion Criteria4

  • A study participant must satisfy the following criteria to be enrolled in this study:
  • Pregnant women aged 15-25 years
  • Able to provide consent for self
  • Malaria positive by rapid diagnostic test (RDT)

Exclusion Criteria3

  • Severe anemia defined as HGB<7 gr/dL, that may be worsened by 10 mL phlebotomy
  • Conditions that in the judgment of the investigator could increase the risk to the volunteer
  • Prior enrollment to the study during the same pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Ouelessebougou Clinical Research Center

Bamako, Mali

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02471378


Related Trials